China has been more of a spectator than an active participant in the global drug development arena. Its biomedical research has lacked funds and innovation, and very few results are being translated into clinical use. Science magazine’s Asia correspondent Dennis Normile looks at the problems that Chinese biomedical research has been facing and what measures Chinese authorities are putting into place to kickstart innovation. getAbstract recommends this concise and informative overview to anyone who needs or wants to know the direction Chinese biomedical research and drug development is heading.
About the Author
Dennis Normile is the Asia correspondent for Science magazine. He writes about research and science policy development, in particular in China and Japan.